Tirzepatide vs Semaglutide: What the Head-to-Head Trial Actually Showed

The core difference is how many hormone receptors each drug activates. Semaglutide (sold as Wegovy for weight loss and Ozempic for type 2 diabetes) is a single-agonist: it mimics one gut hormone, GLP-1 (glucagon-like peptide-1), which slows how fast your stomach empties, signals fullness to the brain, and helps regulate blood sugar.

Tirzepatide (sold as Zepbound for weight loss and Mounjaro for diabetes) is a dual-agonist. It mimics GLP-1 *and* GIP (glucose-dependent insulinotropic polypeptide), a second gut hormone. Researchers think adding GIP improves how fat tissue handles energy and may soften some of the nausea that comes from GLP-1 activity alone, which is one theory for why tirzepatide tends to be better tolerated at higher doses.

Both are once-weekly injections you give yourself with a pen. Both require a gradual dose increase over several months so your gut can adapt — more on that in our guide to [when to increase your GLP-1 dose and when to hold](/blog/glp1-dose-escalation-when-to-increase-and-when-to-hold).

A point of confusion worth clearing up: Mounjaro and Zepbound are the same molecule with different labels, and Ozempic and Wegovy are the same molecule with different labels. The brand name reflects what the FDA approved it *for*, not a different drug. We break that down in [Mounjaro vs Zepbound](/blog/mounjaro-vs-zepbound-same-drug-different-label-2026).

So when people ask "which is stronger," they're really asking whether hitting two receptors beats hitting one. Until 2025, nobody had tested that directly.

Tirzepatide produced 20.2% average weight loss versus 13.7% for semaglutide over 72 weeks (SURMOUNT-5, NEJM 2025). That is a gap of roughly 6.5 percentage points.

SURMOUNT-5 was a phase 3b, open-label trial in adults with obesity who did not have type 2 diabetes. Both groups were titrated to their maximum tolerated dose — up to 15 mg tirzepatide, up to 2.4 mg semaglutide — which matters, because earlier comparisons were indirect guesses based on separate trials run in different populations at different times.

Translated into pounds: a woman starting at 200 lbs would average about 40 lbs lost on tirzepatide and about 27 lbs on semaglutide. Waist circumference told the same story — tirzepatide dropped waistlines by 18.4 cm versus 13.0 cm for semaglutide. That waist number matters more than it sounds, because waist circumference is a rough proxy for visceral fat, the metabolically active fat around your organs that drives insulin resistance and heart risk.

But averages hide a lot. The distributions overlapped substantially. Plenty of women on semaglutide lost 20% or more; plenty on tirzepatide lost under 10%. Response to these medications varies with genetics, dose tolerated, sleep, protein intake, and how much muscle you keep — which is why [strength training on a GLP-1](/blog/strength-training-on-glp1-how-to-preserve-muscle-while-losing-weight) isn't optional if you want the number on the scale to reflect fat loss rather than muscle loss.

Not automatically. Weight loss is one outcome; it isn't the only one that matters, and for some women it isn't even the most important one.

Semaglutide has cardiovascular outcome data that tirzepatide does not yet have. The SELECT trial (NEJM 2023) followed more than 17,600 adults with overweight or obesity and existing cardiovascular disease, without diabetes, and found a 20% reduction in major adverse cardiovascular events — heart attack, stroke, cardiovascular death — over about 40 months. That led to an FDA label expansion. Semaglutide also has the FLOW trial (NEJM 2024) showing a 24% reduction in kidney disease progression events in people with type 2 diabetes and chronic kidney disease.

Tirzepatide has strong data of its own — SURMOUNT-OSA (NEJM 2024) for obstructive sleep apnea, SUMMIT for heart failure with preserved ejection fraction — but the large cardiovascular outcomes trial is still reading out. If you are a woman past menopause with a family history of heart disease, that distinction is worth raising with your clinician, because [cardiovascular risk climbs sharply after the menopause transition](/blog/menopause-heart-disease-risk-what-swan-found).

The second thing averages don't capture: tolerability. In SURMOUNT-5, gastrointestinal side effects led to treatment discontinuation in 5.6% of semaglutide users versus 2.7% of tirzepatide users. Most adverse events in both groups were mild to moderate and clustered during dose escalation. Still, a drug you stop taking has an effectiveness of zero. If nausea is your limiting factor, our guide to [easing GLP-1 nausea](/blog/glp1-nausea-why-it-happens-and-how-to-ease-it) covers the practical fixes before you consider switching.

Access, not efficacy, is what decides this question for most women — and it changes month to month.

Both medications sit on specialty tiers with most commercial insurers, and coverage for weight loss (as opposed to type 2 diabetes) remains patchy. Employer plans increasingly carve out anti-obesity medications entirely. Manufacturer savings programs exist for both — Lilly's for Zepbound, Novo Nordisk's for Wegovy — but eligibility usually requires commercial insurance, which excludes Medicare and Medicaid enrollees.

Both manufacturers now sell direct-to-consumer cash-pay vials at prices well below list, and those prices have moved several times. Our regularly updated breakdown of [GLP-1 savings cards and cash prices](/blog/glp1-savings-cards-cash-prices-lower-cost-2026) has the current numbers, and if your claim was rejected, [how to appeal a GLP-1 prior authorization denial](/blog/glp1-insurance-denial-how-to-appeal-prior-authorization-2026) walks through the paperwork that actually works.

One practical note on switching: if you're currently on semaglutide and want to move to tirzepatide, you do not start at the equivalent "strength." Your clinician will typically restart you at tirzepatide 2.5 mg and titrate up, because there's no validated dose-conversion between the two molecules. Expect a temporary dip in appetite suppression during that transition, and expect the gut side effects to reset with the new escalation.

A third option now exists that didn't a year ago: an oral GLP-1 pill. If needles or refrigeration are your obstacle, see [oral vs injectable GLP-1](/blog/oral-vs-injectable-glp1-which-is-right-for-you).

Both drugs still work in midlife, but the context around them changes — and neither SURMOUNT-5 nor the earlier trials were designed to answer menopause-specific questions.

During the menopause transition, estrogen decline shifts fat storage toward the abdomen and accelerates loss of lean mass. SWAN data show the rate of fat gain roughly doubles in the two years before the final period while lean mass begins to decline. Layer a GLP-1 on top of that and you have two forces pulling at muscle at once: the natural sarcopenia of midlife and the lean-mass loss that accompanies any rapid weight reduction. That's the whole reason we wrote about [the muscle-loss double risk](/blog/glp1-menopause-muscle-loss-the-sarcopenia-double-risk) and about [protein targets specifically for women on a GLP-1 in menopause](/blog/protein-on-glp1-during-menopause-your-daily-target).

The upside is real too. Tirzepatide's larger waist reduction is particularly relevant in midlife, because the visceral fat that accumulates after menopause is the fat most linked to insulin resistance and cardiovascular risk — covered in [why belly fat shifts in menopause](/blog/glp1-menopause-visceral-fat-why-belly-fat-shifts).

And if you're on hormone therapy, you don't have to choose. There's no known pharmacological conflict between HRT and GLP-1 medications; see [HRT and GLP-1 together](/blog/hrt-and-glp1-together-can-you-combine-them). What does need watching is bone density, since rapid weight loss and estrogen decline both reduce bone mass — [that combination is worth a conversation with your clinician](/blog/glp1-bone-density-menopause-protecting-your-bones).

Bring four things to the conversation with your prescriber, and the decision usually makes itself.

1. Your cardiovascular history. If you have established heart disease, or strong risk factors and a post-menopausal risk profile, semaglutide's SELECT data may outweigh tirzepatide's larger weight-loss average. If you also have chronic kidney disease, FLOW strengthens that case further.

2. Your other conditions. Diagnosed obstructive sleep apnea points toward tirzepatide, which has a specific FDA indication for it based on SURMOUNT-OSA. Type 2 diabetes changes which brand and which formulary tier you land on.

3. Your tolerance history. If you've already tried one and stopped because of nausea, vomiting, or [sulfur burps](/blog/glp1-sulfur-burps-why-they-happen-and-how-to-stop-them), the discontinuation gap in SURMOUNT-5 is meaningful — but so is dose strategy. Many women who "failed" a GLP-1 were escalated too fast, not given the wrong drug.

4. What your plan covers. This is often the deciding vote. Ask your pharmacist to run a test claim on both before you commit to a preference.

Whatever you start, give it a fair trial. Meaningful separation between these drugs doesn't appear at week 4 — SURMOUNT-5 ran 72 weeks. And track more than weight: waist circumference, strength, energy, blood pressure, and how quiet the [food noise](/blog/food-noise-on-glp1-what-it-is-and-why-it-quiets) has gotten all tell you whether the medication is doing its job.